Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ("AML"). As announced in December 2024, three AML patients had been treated at the lowest dose ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...

A 42-year-old hypertensive and diabetic male presented to the hospital with complaints of severe weakness, decreased appetite and loss of weight for three months. He also developed difficulty of ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

Researchers at the University of Houston, in collaboration with Baylor College of Medicine, are developing new devices for ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...

Here authors discover that inhibition of guanine nucleotide biosynthesis leads to myeloid differentiation and sensitization to menin inhibitors in leukemia stem cells of MLLr leukemia.